Skip to main content
Erschienen in: Medical Oncology 4/2016

01.04.2016 | Original Paper

Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables

verfasst von: Semra Paydas, Arbil Acikalin, Melek Ergin, Hikmet Celik, Basak Yavuz, Kahraman Tanriverdi

Erschienen in: Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

miRNAs are small RNAs and control the expression of protein-encoding genes. The aim of this study was to determine the association between miRNA profile and clinical variables including age, stage, B symptom, histopathologic subtype, response to treatment, disease-free survival (DFS) and overall survival (OS) in classical Hodgkin lymphoma (cHL). A total of 377 miRNAs were studied by qPCR in 32 cases with cHL, and results were compared with 60 samples taken from cases with reactive lymphadenopathy. Biogazelle qbasePLUS 2.0 software was used to analyze the results. miR-582-3p, miR-525-3p, miR-448, miR-512-3p, miR-642a-5p, miR-876-5p, miR-532-3p, miR-654-5p, miR-128, miR-145-5p, miR-15b-5p, miR-328 and miR-660-5p were found to be decreased in cHL compared with controls. In contrast, miR-34a-5p (2.626-fold), miR-146a-5p (4.32-fold), miR-93-5p (2.347-fold), miR-20a-5p (4.930-fold), miR-339-3p (4.948-fold), miR-324-3p (4.98-fold), miR-372 (7.038-fold), miR-127-3p (8.234-fold), miR-155-5p (4.947-fold), miR-320a (17.502-fold) and miR-370 (21.479-fold) (p < 0.05) were found to be increased in cHL. There was no difference in miRNA profile according to the age, sex, stage, response to treatment, DFS and OS. However, miR-889 was found to be increased in patients with B symptom and miR-127-3p was found to be increased in nodular sclerosing subtype. Some miRNAs increase and some decrease in cHL. However, there was no clinical association between clinical variables and with the majority of the miRNA profile studied in this study. miR-889 and miR-127-3p were related to B symptom and nodular sclerosis subtype, respectively. We need more studies evaluating miRNA profile and clinical outcome in Hodgkin Lymphoma.
Literatur
1.
Zurück zum Zitat Healy NA, Heneghan NA, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer. 2012;131:2215–22.CrossRefPubMed Healy NA, Heneghan NA, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer. 2012;131:2215–22.CrossRefPubMed
2.
Zurück zum Zitat Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160:571–81.CrossRefPubMed Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160:571–81.CrossRefPubMed
3.
Zurück zum Zitat Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.CrossRefPubMedPubMedCentral Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.CrossRefPubMed Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.CrossRefPubMed
5.
Zurück zum Zitat Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.CrossRefPubMedPubMedCentral Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Song G, Gu L, Li J, Tang Z, Liu H, Chen B, Sun X, He B, Pan Y, Wang S, Cho WC. Serum microRNA expression profiling predict response to RCHOP treatment indiffuse large B cell lymphoma patients. Ann Hematol. 2014;93:1735–43.CrossRefPubMed Song G, Gu L, Li J, Tang Z, Liu H, Chen B, Sun X, He B, Pan Y, Wang S, Cho WC. Serum microRNA expression profiling predict response to RCHOP treatment indiffuse large B cell lymphoma patients. Ann Hematol. 2014;93:1735–43.CrossRefPubMed
7.
Zurück zum Zitat Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed
8.
Zurück zum Zitat Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499–505.CrossRefPubMed Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499–505.CrossRefPubMed
9.
Zurück zum Zitat Ansell Stephen M. Hodgkin lymphoma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:772–9.CrossRef Ansell Stephen M. Hodgkin lymphoma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:772–9.CrossRef
10.
Zurück zum Zitat Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ, van den Berg A. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 2009;11:167–76.CrossRefPubMedPubMedCentral Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ, van den Berg A. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 2009;11:167–76.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243–9.CrossRefPubMed Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243–9.CrossRefPubMed
12.
Zurück zum Zitat Van Vlierberghe P, De Weer A, Mestdagh P, Feys T, De Preter K, De Paepe P, Lambein K, Vandesompele J, Van Roy N, Verhasselt B, Poppe B, Speleman F. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol. 2009;147:686–90.CrossRefPubMed Van Vlierberghe P, De Weer A, Mestdagh P, Feys T, De Preter K, De Paepe P, Lambein K, Vandesompele J, Van Roy N, Verhasselt B, Poppe B, Speleman F. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol. 2009;147:686–90.CrossRefPubMed
13.
Zurück zum Zitat Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LHC, Chadburn A, Tuschl T, Knowles DM, Tam W. MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 2008;173:242–52.CrossRefPubMedPubMedCentral Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LHC, Chadburn A, Tuschl T, Knowles DM, Tam W. MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 2008;173:242–52.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E, Monzo M. Regulation of JAK2 bymiR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114:2945–51.CrossRefPubMed Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E, Monzo M. Regulation of JAK2 bymiR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114:2945–51.CrossRefPubMed
15.
Zurück zum Zitat Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alves FJ, Canales M, Estevez M, Menarguez J, Sabin P, Ruiz-Marcellan MC, Lopez A, Sanchez-Godoy P, Burgos F, Santonja C, Lopez J, Piris MA, Garcia JF. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol. 2013;162:336–47.CrossRefPubMed Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alves FJ, Canales M, Estevez M, Menarguez J, Sabin P, Ruiz-Marcellan MC, Lopez A, Sanchez-Godoy P, Burgos F, Santonja C, Lopez J, Piris MA, Garcia JF. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol. 2013;162:336–47.CrossRefPubMed
Metadaten
Titel
Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables
verfasst von
Semra Paydas
Arbil Acikalin
Melek Ergin
Hikmet Celik
Basak Yavuz
Kahraman Tanriverdi
Publikationsdatum
01.04.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0749-5

Weitere Artikel der Ausgabe 4/2016

Medical Oncology 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.